Mangalam Drugs & Organics Limited
Bombay Stock ExchangeTotal Valuation
Mangalam Drugs & Organics Limited carries a market capitalization of 454.44M, placing it among publicly traded companies globally. Its enterprise value stands at 1.46B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 454.44M |
| Enterprise Value | 1.46B |
Share Statistics
Mangalam Drugs & Organics Limited currently has 15.83M shares outstanding.
| Shares Outstanding | 15.83M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.19, and the price-to-book ratio stands at 2.77.
| PE Ratio | N/A |
| PS Ratio | 0.19 |
| PB Ratio | 2.77 |
| P/TBV Ratio | 0.63 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Mangalam Drugs & Organics Limited trades at an EV/EBITDA multiple of 22.50 and an EV/FCF ratio of 9.82. The EV/Sales ratio of 0.63 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 22.50 provides insight into valuation relative to core operating earnings.
| EV / Sales | 0.63 |
| EV / EBITDA | 22.50 |
| EV / EBIT | 22.50 |
| EV / FCF | 9.82 |
Financial Position
Mangalam Drugs & Organics Limited maintains a current ratio of 0.79, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 102.35, indicating elevated leverage, while an interest coverage ratio of -2.01 demonstrates limited ability to service its debt obligations.
| Current Ratio | 0.79 |
| Quick Ratio | 0.02 |
| Debt / Equity | 102.35 |
| Debt / EBITDA | -3.24 |
| Interest Coverage | -2.01 |
Financial Efficiency
| Return on Equity (ROE) | -71.33 |
| Return on Assets (ROA) | -13.03 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.31 |
Taxes
| Income Tax | -41.71M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Mangalam Drugs & Organics Limited's stock has declined approximately -67.30901% over the past 52 weeks. The 50-day moving average sits at 32.67, while the 200-day moving average is 65.81.
| Beta (5Y) | N/A |
| 52-Week Price Change | -67.30901% |
| 50-Day Moving Average | 32.67 |
| 200-Day Moving Average | 65.81 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Mangalam Drugs & Organics Limited generated 2.32B in revenue and converted that into -444.00M in net income, yielding earnings per share of -28.05. EBITDA reached -325.91M, while operating income came in at -325.91M.
| Revenue | 2.32B |
| Gross Profit | 735.74M |
| Operating Income | -325.91M |
| Pretax Income | -485.71M |
| Net Income | -444.00M |
| EBITDA | -325.91M |
| EBIT | -325.91M |
| Earnings Per Share (EPS) | -28.05 |
Balance Sheet
Mangalam Drugs & Organics Limited holds 38.70M in cash and equivalents against 1.05B in total debt, resulting in a net debt position of 1.01B. Total book value stands at 158.28M, with working capital of -408.69M providing operational flexibility.
| Cash & Cash Equivalents | 38.70M |
| Total Debt | 1.05B |
| Net Debt | 1.01B |
| Equity (Book Value) | 158.28M |
| Book Value Per Share | 10.00 |
| Working Capital | -408.69M |
Margins
Mangalam Drugs & Organics Limited operates with a gross margin of 31.69, reflecting its pricing power and cost economics. The operating margin of -14.04 and net profit margin of -19.13 provide insight into operational efficiency.
| Gross Margin | 31.69 |
| Operating Margin | -14.04 |
| Pretax Margin | -20.92 |
| Profit Margin | -19.13 |
| EBITDA Margin | -14.04 |
Scores
Mangalam Drugs & Organics Limited posts an Altman Z-Score of 0.39, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.39 |